GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (OTCPK:NEVPF) » Definitions » EV-to-Revenue

NEVPF (Abliva AB) EV-to-Revenue : 1,266.54 (As of Dec. 12, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Abliva AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Abliva AB's enterprise value is $16.47 Mil. Abliva AB's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $0.01 Mil. Therefore, Abliva AB's EV-to-Revenue for today is 1,266.54.

The historical rank and industry rank for Abliva AB's EV-to-Revenue or its related term are showing as below:

NEVPF' s EV-to-Revenue Range Over the Past 10 Years
Min: -46.29   Med: 330.68   Max: 9400.02
Current: 1281.96

During the past 13 years, the highest EV-to-Revenue of Abliva AB was 9400.02. The lowest was -46.29. And the median was 330.68.

NEVPF's EV-to-Revenue is ranked worse than
96.16% of 1042 companies
in the Biotechnology industry
Industry Median: 7.635 vs NEVPF: 1281.96

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-12-12), Abliva AB's stock price is $0.01. Abliva AB's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00. Therefore, Abliva AB's PS Ratio for today is .


Abliva AB EV-to-Revenue Historical Data

The historical data trend for Abliva AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abliva AB EV-to-Revenue Chart

Abliva AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,427.05 764.58 1,446.80 3,974.83 1,475.05

Abliva AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1,475.05 1,025.52 989.12 1,599.62

Competitive Comparison of Abliva AB's EV-to-Revenue

For the Biotechnology subindustry, Abliva AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abliva AB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abliva AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Abliva AB's EV-to-Revenue falls into.



Abliva AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Abliva AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=16.465/0.013
=1,266.54

Abliva AB's current Enterprise Value is $16.47 Mil.
Abliva AB's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abliva AB  (OTCPK:NEVPF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Abliva AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.01/0
=

Abliva AB's share price for today is $0.01.
Abliva AB's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abliva AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Abliva AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Abliva AB Business Description

Traded in Other Exchanges
Address
Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase. . The company is focused on two projects. KL1333, a powerful NAD+ and NADH regulator, in late-stage development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement therapy, has just completed preclinical development.